Recent trends in inhaled corticosteroid prescriptions and its impact on COPD management: an analysis of the KOLD/KOCOSS cohorts
- Authors
- Lee, Se Hee; Lee, Ji-Hyun; Il Yoon, Ho; Park, Hye Yun; Kim, Tae-Hyung; Yoo, Kwang Ha; Oh, Yeon-Mok; Jung, Ki Suk; Lee, Sang-Do; Lee, Sei Won
- Issue Date
- Sep-2019
- Publisher
- EUROPEAN RESPIRATORY SOC JOURNALS LTD
- Keywords
- COPD - management; Bronchodilators
- Citation
- EUROPEAN RESPIRATORY JOURNAL, v.54
- Indexed
- SCIE
SCOPUS
- Journal Title
- EUROPEAN RESPIRATORY JOURNAL
- Volume
- 54
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/2152
- DOI
- 10.1183/13993003.congress-2019.PA2506
- ISSN
- 0903-1936
- Abstract
- Background: This real-world cohort study was performed in chronic obstructive pulmonary disease (COPD) patients to evaluate the status of inhaled corticosteroid (ICS) prescriptions following the 2017 revision of the GOLD guidelines.
Methods: A total of 1144 patients from KOLD and KOCOSS cohorts, whose final follow-up visits were between 2017 and 2018, were analyzed. Features supporting ICS usage were: a history of asthma, blood eosinophils ≥300 cells/µl, or ≥2 exacerbations in the previous year. Among baseline ICS users, we compared annual total and severe exacerbation rates, based on ICS continuation or withdrawal.
Results: ICS-containing regimens were prescribed for 46.3% of patients at baseline; this decreased to 38.8% in 2017, and long-acting dual bronchodilators were widely used instead. Among ICS users in 2017, 47.5% did not exhibit features supporting ICS usage. ICS was withdrawn in 77 (16.1%) patients during the study period. Annual exacerbation rates were similar between ICS withdrawal and ICS continued groups (0.48 vs. 0.47, p=0.84); however, the ICS withdrawal group exhibited a significantly higher severe exacerbation rate (0.22 vs. 0.12, p=0.03). The proportion of patients with asthma and the baseline annual exacerbation rate were greater in the ICS withdrawal group than in the ICS continued group (56.6% vs. 41%, p=0.01; 0.79 vs. 0.53, p<0.001).
Conclusions: Prescriptions of ICS in COPD patients decreased with increased use of long-acting dual bronchodilators. ICS withdrawal might impact severe exacerbation; therefore it should be decided with consideration of potential risk and benefits of ICS based on patients’ characteristics.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/2152)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.